This is Nanologica’s first order in the North American market for evaluation of the company’s silica at production scale. The order value is USD 140,700, which corresponds to appx. SEK 1.3 million at today's exchange rate.

"This is an important order for us as it means that we are now taking a step into the North American market. So far, our main focus has been on markets in Asia, especially China, where we have taken recurring production orders for NLAB Saga®. It is therefore very gratifying that we are now getting started in the US as well", Nanologica's CEO Andreas Bhagwani comments.

The order will be delivered during the third quarter.

For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Thanks to their efficient and long-lasting purification, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of an increased demand for drugs for the treatment of diabetes and obesity. The Company's mission is to increase access to cost-effective medicines through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The Company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.